Cargando…
Antibody–Drug Conjugates—A Tutorial Review
Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 ADCs currently in clinical development and eleven ADCs (nine containing small-molecule payloads and two with biological toxi...
Autores principales: | Baah, Stephanie, Laws, Mark, Rahman, Khondaker Miraz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156828/ https://www.ncbi.nlm.nih.gov/pubmed/34063364 http://dx.doi.org/10.3390/molecules26102943 |
Ejemplares similares
-
Antibiotic resistance breakers: current approaches and future directions
por: Laws, Mark, et al.
Publicado: (2019) -
Noncytotoxic Pyrrolobenzodiazepine–Ciprofloxacin
Conjugate with Activity against Mycobacterium tuberculosis
por: Picconi, Pietro, et al.
Publicado: (2019) -
From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
por: Mantaj, Julia, et al.
Publicado: (2016) -
Evaluation of Antibiotic Resistance Mechanisms in Gram-Negative Bacteria
por: Gauba, Anusha, et al.
Publicado: (2023) -
Effectiveness of Efflux Pump Inhibitors as Biofilm Disruptors and Resistance Breakers in Gram-Negative (ESKAPEE) Bacteria
por: Reza, Akif, et al.
Publicado: (2019)